Stay Informed & Engaged.

ST. LOUIS, Sept. 9, 2025 /PRNewswire/ – Panome Bio, a leading provider of multi-omic services, announced a first of its kind commercial offering applying their leading discovery metabolomics capabilities to Formalin-Fixed Paraffin-Embedded (FFPE) samples. Building on its recent Clinical Laboratory Improvement Amendments (CLIA) certification, Panome Bio is now uniquely positioned to offer broad and unbiased metabolomic analysis of traditionally challenging FFPE samples.

Panome Bio has made FFPE samples accessible for discovery metabolomics through innovations in sample preparation and data analysis. This breakthrough unlocks a critical resource in clinical and translational research, allowing for the analysis of archived tissues and associated clinical data. This technology enables more expansive retrospective studies and the discovery of new drug targets and biomarkers. The new offering also integrates directly into existing pathology workflows, eliminating the need for labs to adopt costly new handling procedures and enhancing Panome Bio’s comprehensive multi-omic suite.

Ginger Zhou, President at GENEWIZ and partner of Panome Bio, said “The ability to perform metabolomics on FFPE samples is a major step forward for the multi-omics field. By adding this crucial layer of metabolomics data to discovery work in FFPE, we can unlock new insights from clinical archives as scientists accelerate paths to patient stratification and more targeted therapies.”

“At Panome Bio, we are constantly striving to provide researchers with the most powerful tools to unravel complex biological questions,” explains Edward Weinstein, CEO of Panome Bio. “By extending our cutting-edge metabolomics platform to include FFPE samples, we are enabling our clients to unlock a wealth of historical biological information, which is particularly valuable for biomarker discovery and understanding disease mechanisms across large, longitudinal cohorts.”